Analytical Data
-
Gene name
MMAE
- Application
-
Alternative Names
MMAE；(3R)-3-[(carboxymethyl)amino]fatty acid oxygenase/decarboxylase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
B2HKM3
-
Expression Region
1-289aa
-
AA Sequence
MTLNVKGEGLGAQITGVDPKNLDDITTDEIRDIVYANKLVILKDVNPSPEEFLKLGKIVGQIVPYYEPMYHHEDHPEIFVSSTEEGQGVPKTGAFWHIDYMFMPEPFAFSMVLPLAVPGHDRGTYFIDLAKVWQSLPAAQQAPARGTLSTHDPRRHIKIRPSDVYRPIGEVWDEISRATPPIKWPTVIRHPKTGEEILYICATGTTKIEDKDGNLVDPAVLAELLAATGQLDPEYNSPFIHTQHYEVGDIILWDNRVLMHRAKHGTASGTLTTYRLTMLDGLETPGYPA
-
Molecular Weight
32.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MMAE, or Monomethyl Auristatin E, is a potent tubulin inhibitor that has gained significant attention in the field of targeted cancer therapy, particularly in the context of antibody-drug conjugates (ADCs). The use of MMAE is particularly promising due to its ability to selectively disrupt the microtubule network in cancer cells, leading to cell cycle arrest and apoptosis. Research into MMAE-recombinant proteins aims to enhance the therapeutic efficacy and specificity of ADCs by improving the delivery of MMAE to tumor tissues while minimizing off-target effects. The incorporation of MMAE into antibody constructs facilitates the targeted delivery of this cytotoxic agent directly to cancer cells, leveraging the specificity of antibodies for tumor-associated antigens. This innovative approach not only holds potential for treating various malignancies but also aims to overcome challenges associated with traditional chemotherapy, such as systemic toxicity and drug resistance. Recent studies have focused on optimizing the conjugation techniques and evaluating the pharmacokinetics and biodistribution of MMAE-recombinant proteins, paving the way for the development of next-generation ADCs. As the understanding of cancer biology and drug delivery mechanisms advances, ongoing research into MMAE and its applications in targeted therapies continues to unveil new possibilities for improving patient outcomes in oncology.
